Published in final edited form as:

J Org Chem. 2015 December 18; 80(24): 12635–12640. doi:10.1021/acs.joc.5b02199.

Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis

Lindsey R. Orgren^a, Emily E. Maverick^b, and Christopher C. Marvin^c

Department of Chemistry, Hendrix College, 1600 Washington Avenue, Conway, Arkansas, 72032, United States

Christopher C. Marvin: christopher.marvin@abbvie.com

Abstract

(±)-Tetrabenazine was synthesized in six steps from commercially available compounds. The key cyclization substrate was assembled rapidly via Baylis-Hillman and aza-Michael reactions. Annulation of the final ring was achieved through visible light photocatalysis, wherein carbon-carbon bond formation was driven by the oxidation of a tertiary amine. Solvent played a critical role in the photoredox cyclization outcome—whereas methanol led to a mixed ketal, acetonitrile/water (10:1) gave direct cyclization to (±)-tetrabenazine and occurred more rapidly.

Graphical abstract

First prepared in the 1950's as an antipsychotic,^{1–2} tetrabenazine (TBZ, (±)-**1**, Fig. 1) has reemerged as a therapeutically useful compound for the treatment of hyperkinetic disorders. An important milestone for this benzo[*a*]quinolizine came in 2008, when the FDA approved the racemic mixture of **1** for the treatment of Huntington's chorea in the United States.^{3–5} Metabolically TBZ is rapidly reduced to dihydrotetrabenazine (DTBZ, (±)-**2**), which is responsible for most of the pharmacological activity. Both TBZ and its metabolite, DTBZ, reversibly bind to vesicular monoamine transporter 2 (VMAT2) with nanomolar affinities.^{6–7} VMAT2 is responsible for shuttling monoamines into the presynaptic vesicles from the neuronal cytoplasm.⁸ Inhibition of VMAT2 directly decreases neurotransmitters available for release, and further indirectly depletes monoamine levels, as those stranded in cytoplasm become degraded by monoamine oxidases. The value of these compounds

Correspondence to: Christopher C. Marvin, christopher.marvin@abbvie.com.

^aDepartment of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, WI 53706

^bBiomedical Sciences Department, 1617 Campus Delivery, Colorado State University, Fort Collins, CO 80523

^cAbbVie, Inc., Discovery Chemistry and Technology, 1 North Waukegan Rd., North Chicago, IL 60064

SUPPORTING INFORMATION

General experimental procedures, ¹H and ¹³C NMR spectra, and comparisons of the NMR data for (±)-**1** and (±)-**2** with literature data are provided. This material is available free of charge via the Internet at <http://pubs.acs.org>.

extends beyond the treatment of hyperkinetic disorders. The high VMAT2 affinity of (+)-(2*R*,3*R*,11*bR*)-DTBZ (K_i 0.97 nM) has spurred the development of radiolabeled analogs that are valuable imaging agents for diagnosing neurological conditions.^{9–15} Furthermore, Parkinsonian tremors can be modeled by dosing rodents with TBZ to induce tremulous jaw movements.¹⁶

TBZ and DTBZ's compelling pharmacology has stimulated the development of several methods for the preparation of these alkaloids,^{2,17–23} as well as the synthesis of numerous analogs.^{11,24–27} Our synthetic approach was inspired by a late-stage oxidative aza-Prins cyclization strategy that was reported by Cho, Min, and co-workers (Scheme 1A).²¹ In that work, stoichiometric DDQ oxidized tertiary amine **3** to an iminium ion, which cyclized with a tethered allylsilane to provide **4**. Tetrabenazine and dihydrotetrabenazine were subsequently obtained through additional oxidation state adjustments. A key finding of their work was that the iminium ion cyclization occurred stereoselectively, establishing the correct relative stereochemistry between C-11*b* and C3. We envisioned that a related approach involving an oxidative Mannich cyclization would offer advantages with respect to step and redox economies (Scheme 1B).²⁸ In principle the cyclization substrate would be available through the conjugate addition of tetrahydroisoquinoline **7** to an appropriately functionalized enone, exemplified by **8a/8b**.

Furthermore, we recognized this as an opportunity to examine a more environmentally benign alternative to stoichiometric oxidants in the context of a target-directed synthesis. A number of aerobic methods have been developed for oxidative Mannich-type couplings of carbon nucleophiles with relevant tertiary amines,²⁹ including those mediated by transition metals, such as Cu^{30–33} and Fe,^{34–35} as well as other catalytic radical initiators, such as triarylammonium radical salts,³⁶ I₂,^{37–38} and SO₂Cl₂.³⁹ Visible light photocatalysis has emerged as a capable and environmentally benign method for driving redox processes.^{40–46} Specifically, Stephenson, and others, have shown that *N*-aryltetrahydroisoquinolines are excellent substrates for visible light photoredox catalysis.^{47–53} We elected to pursue photoredox catalysis for the cyclization of **6** to TBZ based on our own work in this area that demonstrated *N*-alkylated tetrahydroisoquinolines, as well as other tertiary amines, remain viable substrates for oxidation under these conditions.⁵⁴ *N*-Alkylated tetrahydroisoquinolines⁵⁵ have a slightly more positive redox potentials compared to *N*-aryl analogs.^{56–57} This could partially explain why oxidative coupling reactions of *N*-alkylated tetrahydroisoquinolines are not as developed as their *N*-aryl counterparts.⁵⁸ Diverse nucleophiles can be coupled with iminium ions generated under photoredox conditions, including enol ethers and ketones, although the latter must be activated through enamine catalysis.^{59–62} Although intermolecular couplings of *N*-aryltetrahydroisoquinolines generally require an excess of the nucleophilic partner, we reasoned that the proposed cyclization of **6a/6b** to TBZ would be facilitated by the high effective concentration inherent with an intramolecular process.

An important question was whether a ketone or an enol ether would be optimal for the cyclization (Scheme 2). This was addressed through the rapid preparation of **6a** in 93% yield through the reaction of tetrahydroisoquinoline **7** and methyl vinyl ketone in the presence of aqueous NaOH. Unfortunately, we were unable to identify conditions for the direct

cyclization of **6a** to **9** under standard photoredox conditions with Ru(bpy)₃Cl₂. Cyclization of **6a** was also attempted in the presence of proline or pyrrolidine·TFA, conditions that have been effective for oxidative couplings of ketones with tetrahydroisoquinoline,^{61–62} but annulation did not occur in this case. ¹H NMR analysis of the crude reaction mixture confirmed the presence of starting material **6a** and a component whereby the benzylic position of tetrahydroisoquinoline ring had been oxidized to give amide. Oxidation of some of this material to an amide was supported by the disappearance of its benzylic CH₂ singlet at 3.5 ppm and the downfield shift of an aromatic CH singlet from 6.51 to 7.55 ppm in the ¹H NMR spectrum. Our group, as well as others, has observed the oxidation of tetrahydroisoquinolines to amides under photoredox conditions.^{54,63–65} We reasoned that the low levels of nucleophile, formed through keto/enol tautomerization or via catalytic formation of the enamines through 2° amine catalysis, was insufficient to compete with the undesired oxidation pathway. Thus, we converted **6a** to TIPS enol ether **10** and found that it cyclized slowly under photoredox conditions in MeOH to provide a mixed methyl triisopropylsilyl ketal that was immediately hydrolyzed to ketone **9** (28% yield for two steps). Two factors contributed to the poor yield of **9**. Conversion for the cyclization of **10** to the mixed ketal was incomplete, even after 4 d, and ketone **9** was difficult to purify by chromatography as it co-eluted with TIPSOH. We attempted the photoredox cyclization of **10** in CH₃CN/H₂O (10:1) in hopes of avoiding the formation of the mixed ketal and the extra hydrolysis step. Fortunately, **10** cyclized directly to **9** in 51% yield after only 2 d of irradiation in this system. Gagné has noted that water as a co-solvent can improve the rates of photocatalytic reactions and posited that this rate enhancement stems from resolution of the catalyst after reductive quenching, which decreases the rate of competing back-transfer reactions.⁶⁶

Pleased that the photoredox cyclization would be a viable approach, we turned our attention to the preparation of branched substrate **6b** (Scheme 3). In addition to directly providing TBZ, the cyclization of **6b** should be more facile compared to **6a** due to gauche interactions present within the side chain, which should serve to pre-organize the side chain and decrease the activation energy. The first step to prepare this substrate involved modified conditions for a known Baylis-Hillman reaction between methyl vinyl ketone (**8a**) and isobutyraldehyde,⁶⁷ followed by acetylation to provide **12**. Treating **12** with commercially available tetrahydroisoquinoline salt **7** in the presence of aqueous hydroxide promoted rapid conjugate addition, which was accompanied by spontaneous β-elimination of acetate, forming enone **14** as a 6:1 mixture of *E*:*Z* isomers. Selective reduction of the alkene in **14** was not trivial—several conditions for 1,4-hydride delivery instead predominantly gave the undesired 1,2-reduction product.^{68–71} Hydrogenation under acidic conditions ultimately proved to be rapid and high yielding process, giving **6b** in 79% yield. Addition of TFA was essential in this reaction, as hydrolysis of the benzylic amine and other side products were formed in its absence. Standard conditions were then used to convert **6b** to TIPS enol ether **15**, which could be purified by chromatography.

Photoredox cyclization of **15** was accomplished using a blue LED light source with the standard Ru(bpy)₃Cl₂ catalyst. NMR analysis of the resulting mixed ketal **16** was complicated by the presence of multiple diastereomers, so it was immediately hydrolyzed by

refluxing in aqueous HCl to provide ($\pm$)-tetrabenazine (**1**) in 33% yield over two steps (5:1 dr). Although this represented a modest improvement in yield compared to the oxidative cyclization of **10** in MeOH, this sequence remained relatively inefficient due to incomplete conversion after 3 d and the need for an additional step to hydrolyze the ketal. Once again, CH₃CN/H₂O was a superior solvent system providing complete conversion of **15** to ($\pm$)-tetrabenazine after only 16 h.⁶⁶ It is interesting to note that both solvent systems ultimately provided **1** with identical diastereoselectivity. Unfortunately, we were unable to separate these diastereomers and thus could not investigate whether this is a kinetic or thermodynamic ratio. Finally, tetrabenazine (**1**) was reduced to dihydrotetrabenazine (**2**) by NaBH₄ reduction. The diastereoselectivity for this reduction was consistent with Rishel's results,¹⁸ where **2** was formed in 73% yield as a 95:5 mixture, favoring the shown α -diastereomer.

In summary, ($\pm$)-tetrabenazine was prepared in six steps from commercially available materials. Application of the Baylis-Hillman and aza-Michael reactions enabled the rapid preparation of the tetrabenazine framework. Key observations from photoredox cyclization included the identification of silyl enol ether as the optimal nucleophile, and the critical role of solvent. Whereas cyclization of **15** in methanol led to the formation of mixed ketals, the desired ketone was obtained directly by changing the solvent to acetonitrile/water, which also improved the reaction rate. This work demonstrates the viability of photoredox catalysis as a key step for the synthesis of polycyclic alkaloids.

EXPERIMENTAL SECTION

4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1*H*)-yl)butan-2-one (**6a**)

Methyl vinyl ketone (1 mL, 11.0 mmol) was added to a solution of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (1.32 g, 5.74 mmol) in 2 M aqueous NaOH (3.5 mL). After stirring rapidly for 25 min, the reaction was diluted with water (20 mL), and extracted with ether (3 x 15 mL). The combined organic layers were dried (Na₂SO₄) and concentrated under reduced pressure to provide ketone **6a** (5.36 g, 93%) as light tan syrup. This material was used immediately without further purification. ¹H NMR (CDCl₃) δ 6.59 (1H, s), 6.52 (1H, s), 3.845 (3H, s), 3.838 (3H, s), 3.56 (2H, br s), 2.85-2.80 (4H, comp), 2.75-2.71 (4H, comp), 2.21 (3H, s); ¹³C NMR (CDCl₃) δ 207.9 (C), 147.5 (C), 147.2 (C), 126.1 (C), 125.9 (C), 111.2 (CH), 109.3 (CH), 55.9 (CH₃), 55.8 (CH₃), 55.6 (CH₂), 52.4 (CH₂), 51.0 (CH₂), 41.7 (CH₂), 30.2 (CH₃), 28.5 (CH₂); IR (film) 2912, 2833, 1709, 1516, 1226, 1129, 749 cm⁻¹; HRMS (CI) *m/z* 264.1604 [C₁₅H₂₂NO₃ (M+1) requires 264.1600].

6,7-Dimethoxy-2-(3-((triisopropylsilyl)oxy)but-3-en-1-yl)-1,2,3,4-tetrahydroisoquinoline (**10**)

Triethylamine (1 mL, 7.17 mmol) and TIPSOTf (1 mL, 3.72 mmol) were added sequentially to a room temperature solution of ketone **6a** (648.9 mg, 2.46 mmol) in CH₂Cl₂ (15 mL). After 1 h the reaction mixture was treated with 2 M aqueous NaOH (50 mL). The resulting layers were separated and the aqueous phase was extracted with CH₂Cl₂ (3 x 50 mL). The combined organic layers were dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by flash chromatography (alumina), eluting with EtOAc/hexanes (10:90, then 15:85) to provide TIPS enol ether **10** (723.6 mg, 70%) as a light yellow oil. ¹H

NMR (CDCl₃) δ 6.59 (1H, s), 6.52 (1H, s), 4.06 (2H, br s), 3.85 (3H, s), 3.84 (3H, s), 3.60 (2H, s), 2.83 (2H, t, J = 5.5 Hz), 2.77-2.73 (4H, comp), 2.38 (2H, AA'XX'), 1.22 (2H, m), 1.10 (18H, d, J = 7.0 Hz), 1.07 (1H, m); **¹³C NMR** (CDCl₃) δ 158.0 (C), 147.4 (C), 147.1 (C), 126.6 (C), 126.1 (C), 111.3 (CH), 109.4 (CH), 89.6 (CH₂), 56.2 (CH₂), 55.9 (CH₃ x 2), 55.6 (CH₂), 51.1 (CH₂), 34.9 (CH₂), 28.7 (CH₂), 18.0 (CH₃ x 6), 12.6 (CH x 3); **IR** (film) 2944, 2866, 1517, 1216, 748 cm⁻¹; **HRMS** (CI) m/z 420.2927 [C₂₄H₄₂NO₃Si (M+1) requires 420.2934].

(±)-9,10-Dimethoxy-3,4,6,7-tetrahydro-1H-pyrido[2,1-a]isoquinolin-2(11bH)-one (9)

A 20 mL vial was charged with a solution of TIPS enol ether **10** (270 mg, 0.643 mmol) and Ru(bpy)₃Cl₂ (5.6 mg, 0.0075 mmol) in MeOH (7.6 mL). The vial was sealed with a rubber septa, opened to the air with an 18 gauge needle, and was irradiated using a blue LED strip for 4 d at 45 °C. Although incomplete by TLC, solvent was removed under reduced pressure and the residue was treated with 1 M aqueous HCl (4 mL), MeOH (1 mL) and was refluxed for 1.5 h. The reaction mixture was cooled and treated with 2 M aqueous NaOH (10 mL). The resulting basic solution was extracted with CH₂Cl₂ (3 x 10 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel), eluting with MeOH/CH₂Cl₂ (5:95) to provide **9** (47 mg, 28%) as a light yellow, waxy, solid. **mp** 153–154 °C; **¹H NMR** (CDCl₃) δ 6.63 (1H, s), 6.54 (1H, s), 3.86 (3H, s), 3.84 (3H, s), 3.52 (1H, dd, J = 12.4, 2.3 Hz), 3.29 (1H, m), 3.16-3.08 (2H, comp), 2.91 (1H, app dt, J = 14.7, 2.8 Hz), 2.75-2.69 (3H, comp), 2.61 (1H, app td, J = 12.8, 6.4 Hz), 2.49 (1H, dd, J = 14.2, 12.0 Hz), 2.44 (1H, app dt, J = 11.5, 2.3 Hz); **¹³C NMR** (CDCl₃) δ 208.8 (C), 147.7 (C), 147.4 (C), 128.4 (C), 126.1 (C), 111.3 (CH), 107.6 (CH), 61.5 (CH₃), 55.9 (CH₃), 55.8 (CH), 54.7 (CH₂), 50.8 (CH₂), 47.6 (CH₂), 41.1 (CH₂), 29.3 (CH₂); **IR** (AT-IR) 1708, 1692 cm⁻¹; **HRMS** (CI) m/z 262.1437 [C₁₅H₂₀NO₃ (M+1) requires 262.1443].

One-Step Preparation of (±)-9,10-Dimethoxy-3,4,6,7-tetrahydro-1H-pyrido[2,1-a]isoquinolin-2(11bH)-one (9)

A 20 mL vial was charged with a solution of TIPS enol ether **10** (205 mg, 0.49 mmol) and Ru(bpy)₃Cl₂ (7.8 mg, 0.0104 mmol) in CH₃CN (4 mL) and water (0.4 mL). The vial was sealed with a rubber septa, opened to the air with an 18 gauge needle, and was irradiated using a blue LED strip for 2 d. CH₂Cl₂ (10 mL) and 10% w/w aqueous NaOH (10 mL) were added to the reaction mixture. The layers were separated and the aqueous phase was extracted with CH₂Cl₂ (4 x 10 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure. Filtration through a plug of alumina, trituration with hexanes, provided **9** as an off-white solid. Characterization data was identical for **9** as prepared above through the two-step procedure.

2-Methyl-4-methylene-5-oxohexan-3-yl acetate (12)⁷²

A mixture of methyl vinyl ketone (6 mL, 74 mmol), isobutyraldehyde (8.5 mL, 93 mmol), 1,4-diazabicyclo[2.2.2]octane (1.64 g, 14.6 mmol), and 2,6-di-*tert*-butyl-4-methylphenol (122.4 mg, 0.55 mmol) was stirred overnight. The reaction mixture was diluted with ether (200 mL) and washed with 2 M aqueous HCl (2 x 50 mL), followed by brine (50 mL). The organic phase was dried (Na₂SO₄) and concentrated under reduced pressure to give the

Baylis-Hillman adduct as an orange-colored oil (8.18 g). This oil was dissolved in CH₂Cl₂ (150 mL) and treated, in sequence, with pyridine (3 mL, 37.4 mmol) and acetyl chloride (2.4 mL). Once complete, as monitored by GC-MS, the reaction mixture was diluted with CH₂Cl₂ (100 mL) and washed with 2 M aqueous HCl (100 mL x 3), followed by 2 M aqueous NaOH (100 mL). The organic phase was dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by flash chromatography (silica), eluting with EtOAc/hexanes (15:85 then 2:8) to give enone **12** (5 g, 46%) as a clear, colorless, oil. **¹H NMR** (CDCl₃) δ 6.15 (1H, s), 5.88 (1H, d, *J* = 0.9 Hz), 5.51 (1H, dd, *J* = 5.5, 0.9 Hz), 2.35 (3H, s), 2.08 (3H, s), 1.96 (1H, m), 0.9 (3H, d, *J* = 6.9 Hz), 0.86 (3H, d, *J* = 6.9 Hz); **¹³C NMR** (CDCl₃) δ 197.9 (C), 170.0 (C), 147.5 (C), 125.4 (CH₂), 75.3 (CH), 31.3 (CH₃), 26.1 (CH₃), 21.0 (CH), 19.0 (CH₃), 16.9 (CH₃); **IR** (film) 2967, 2876, 1735, 1677, 1367, 1230, 1023 cm⁻¹; **HRMS** (CI) *m/z* 185.1179 [C₁₀H₁₇O₃ (M+1) requires 185.1178].

3-((6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1*H*)-yl)methyl)-5-methylhex-3-en-2-one (**14**)

6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (**7**) (2.03 g, 8.84 mmol) and enone **12** (1.93 g, 10.47 mmol) were suspended in 2 M aqueous NaOH (6.5 mL) and stirred at ambient temperature for 1 h. The reaction mixture was treated with aqueous 2 M HCl (125 mL) and then washed with ether (75 mL x 2). The pH of the aqueous layer was adjusted to 11 by addition of 2 M aqueous NaOH (150 mL), and was then extracted with CH₂Cl₂ (3 x 80 mL). The combined organic layers were washed with brine (75 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The residue was purified by flash chromatography (silica), eluting with MeOH/CH₂Cl₂ (1:9) to give enone **14** (2.336 g, 83%) as a clear, colorless, oil (6:1 mixture of *E:Z* isomers). *Characterization is provided for the major isomer.* **¹H NMR** (CDCl₃) δ 6.57 (1H, s), 6.55 (1H, d, *J* = 10.0 Hz), 6.49 (1H, s), 3.84 (3H, s), 3.83 (3H, s), 3.52 (2H, s), 3.40 (2H, s), 2.88 (1H, dsept, *J* = 10.0, 6.4 Hz), 2.75 (2H, t, *J* = 5.5 Hz), 2.66 (2H, t, *J* = 5.5 Hz), 2.37 (3H, s), 1.07 (6H, d, *J* = 6.4 Hz); **¹³C NMR** (CDCl₃) δ 200.4 (C), 152.5 (CH), 147.3 (C), 147.0 (C), 135.6 (C), 126.7 (C), 126.2 (C), 111.2 (CH), 109.3 (CH), 55.8 (CH₃ x 2), 55.4 (CH₂), 51.9 (CH₂), 50.3 (CH₂), 28.7 (CH₂), 28.1 (CH), 26.4 (CH₃), 22.3 (CH₃ x 2); **IR** (film) 2958, 2868, 2835, 1665, 1517, 1254, 1226, 1126, 909, 727 cm⁻¹; **HRMS** (CI) *m/z* 318.2066 [C₁₉H₂₈NO₃ (M+1) requires 318.2069],

(±)-3-((6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1*H*)-yl)methyl)-5-methylhexan-2-one (**6b**)

A solution of enone **14** (2.47 g, 7.78 mmol) and trifluoroacetic acid (1.19 mL, 15.57 mmol) in MeOH (70 mL) was added to a flask containing 10% w/w Pd/C (0.33 g). Hydrogen was bubbled through the resulting suspension for 20 min. After completion by TLC the reaction mixture was filtered through Celite, treated with 2 M aqueous NaOH (100 mL), and the extracted with CH₂Cl₂ (3 x 100 mL). The combined organic extractions were dried (Na₂SO₄) and concentrated under reduced pressure. An analytically pure sample was obtained by flash chromatography (silica), eluting with MeOH/CH₂Cl₂ (1:9) to give ketone **6b** (1.96 g, 79%) as a light yellow solid. **mp** 62–65.5 °C; **¹H NMR** (CDCl₃) δ 6.56 (1H, s), 6.50 (1H, s), 3.82 (3H, s), 3.81 (3H, s), 3.60 (1H, d, *J* = 14.6 Hz), 3.46 (1H, d, *J* = 14.6 Hz), 2.93 (1H, m), 2.82–2.72 (4H, comp), 2.57 (1H, ddd, *J* = 10.5, 6.9, 5.3 Hz), 2.44 (1H, dd, *J* = 11.5, 5.7 Hz), 2.15 (3H, s), 1.57–1.47 (2H, comp), 1.23 (1H, m), 0.91 (3H, d, *J* = 6.0 Hz), 0.88 (3H, d, *J* = 6.0 Hz); **¹³C NMR** (CDCl₃) δ 212.4 (C), 147.3 (C), 147.0 (C), 126.4 (C),

126.1 (C), 111.2 (CH), 109.2 (CH), 60.7 (CH₂), 55.9 (CH₂), 55.8 (CH₃ x 2), 50.9 (CH₂), 49.0 (CH), 39.3 (CH₂), 28.8 (CH₃), 28.6 (CH₂), 26.1 (CH), 23.0 (CH₃), 22.2 (CH₃); **IR** (film) 2954, 2869, 2836, 1709, 1517, 725 cm⁻¹; **HRMS** (CI) *m/z* 320.2226 [C₁₉H₃₀NO₃ (M +1) requires 320.2226].

(±)-6,7-Dimethoxy-2-(4-methyl-2-(1-((triisopropylsilyl)oxy)vinyl)pentyl)-1,2,3,4-tetrahydroisoquinoline (15)

Ketone **6a** (510 mg, 1.60 mmol) was dissolved in CH₂Cl₂ (11 mL), followed by the sequential addition of Et₃N (0.7 mL, 5.02 mmol), and TIPSOTf (0.65 mL, 2.42 mmol). After 30 min, the reaction mixture was diluted with CH₂Cl₂ (50 mL) and 2 M aqueous NaOH (50 mL). The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 x 50 mL). All organic extractions were combined, then dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by flash chromatography (alumina), eluting with EtOAc/hexanes (1:9) to give TIPS enol ether **15** (610 mg, 80%) as a clear, colorless, oil. **¹H NMR** (CDCl₃) δ 6.58 (1H, s), 6.52 (1H, s), 4.00 (1H, br s), 3.98 (1H, br s), 3.84 (3H, s), 3.83 (3H, s), 3.54 (2H, ABq, *J*_{AB} = 14.6 Hz, δ = 0.06 ppm); 2.80-2.72 (3H, comp), 2.65-2.58 (2H, comp), 2.48-2.39 (2H, comp), 1.69 (1H, m), 1.49 (1H, ddd, *J* = 13.5, 10.5, 3.9 Hz), 1.27-1.18 (3H, comp), 1.09 (18H, d, *J* = 6.9 Hz), 1.06 (1H, m), 0.9 (6H, app d, *J* = 6.9 Hz); **¹³C NMR** (CDCl₃) δ 160.0 (C), 147.2 (C), 147.0 (C), 127.2 (C), 126.5 (C), 111.2 (CH), 109.3 (CH), 88.9 (CH₂), 61.8 (CH₂), 56.0 (CH₂), 55.9 (CH₃ x 2), 51.2 (CH₂), 42.6 (CH), 39.8 (CH₂), 28.8 (CH₂), 25.4 (CH), 23.8 (CH₃), 21.6 (CH₃), 18.1 (CH₃ x 6), 12.8 (CH x 3); **IR** (film) 2944, 2865, 1612 (weak), 1517, 1256, 1228, 1016, 753, 680 cm⁻¹; **HRMS** (CI) *m/z* 474.3399 [C₂₈H₄₈NO₃Si (M-1) requires 474.3403].

(±)-3-Isobutyl-9,10-dimethoxy-3,4,6,7-tetrahydro-1*H*-pyrido[2,1-*a*]isoquinolin-2(1*bH*)-one [(±)-tetrabenazine, TBZ, (±)-1]

A 25 mL round bottom flask was charged with TIPS enol ether **15** (240.4 mg, 0.505 mmol), Ru(bpy)₃Cl₂ (7 mg, 0.0093 mmol), and CH₃CN/H₂O (10:1, 4.4 mL). The flask was equipped with a magnetic stir bar and septa, which was pierced with an 18 gauge needle, and irradiated with the light produced from a 8.5 W blue LED strip for 16 h at 45 °C. CH₂Cl₂ (10 mL) and 2 M aqueous NaOH (5 mL) were added to the reaction mixture. The layers were separated and the aqueous phase was extracted with CH₂Cl₂ (4 x 10 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by flash chromatography (alumina), eluting with EtOAc/hexanes (15:85) to give (±)-tetrabenazine (**1**) (89.2 mg, 56%) as a white crystalline solid (5:1 dr). **mp** 108–110 °C; *Characterization is provided for the major diastereomer.* **¹H NMR** (CDCl₃) δ 6.62 (1H, s), 6.55 (1H, s), 3.86 (3H, s), 3.83 (3H, s), 3.51 (1H, br d, *J* = 10.5 Hz), 3.29 (1H, dd, *J* = 11.5, 6.4 Hz), 3.18-3.07 (2H, comp), 2.90 (1H, dd, *J* = 13.7, 3.0 Hz), 2.78-2.72 (2H, comp), 2.64-2.51 (2H, comp), 2.36 (1H, t, *J* = 11.5 Hz), 1.80 (1H, ddd, *J* = 14.0, 8.7, 5.5 Hz), 1.67 (1H, comp), 1.04 (1H, ddd, *J* = 13.7, 7.3, 5.9 Hz), 0.92 (3H, d, *J* = 5.0 Hz), 0.91 (3H, d, *J* = 5.0 Hz); **¹³C NMR** (CDCl₃) δ 210.2 (C), 147.7 (C), 147.4 (C), 128.4 (C), 126.0 (C), 111.3 (CH), 107.7 (CH), 62.4 (CH), 61.4 (CH₂), 55.9 (CH₃), 55.8 (CH₃), 50.5 (CH₂), 47.6 (CH₂), 47.5 (CH), 35.0 (CH₂), 29.3 (CH₂), 25.3 (CH), 23.2 (CH₃), 22.0 (CH₃); **IR**

(AT-IR) 2920, 2862, 1699, 1515, 1463, 1257, 882 cm^{-1} ; **HRMS** (CI) m/z 318.2073 [$\text{C}_{19}\text{H}_{28}\text{NO}_3$ (M+1) requires 318.2069].

(±)-3-Isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol [α-dihydrotetrabenazine, DTBZ, (±)-2]

A solution of (±)-**1** (101.7 mg, 0.32 mmol) in EtOH (3 mL) was cooled to 0 °C and treated with NaBH_4 (42 mg, 1.11 mmol). After 1 h, 2 M aqueous NaOH (15 mL) was added, and the resulting mixture was extracted with CH_2Cl_2 (4 x 10 mL). The combined organic extracts were dried (Na_2SO_4) and concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel), eluting with MeOH/ CH_2Cl_2 (10:250) to give α-dihydrotetrabenazine (±)-**2** (70.2 mg, 70%) as a white solid and 4.2 mg (4%) of the 2-epi-dihydrotetrabenazine. **α-dihydrotetrabenazine** (major diastereomer): **^1H NMR** (CDCl_3) δ 6.68 (1H, s), 6.58 (1H, s), 5.30 (1H, s), 3.85-3.84 (6H, comp), 3.40 (1H, app td, J = 10.5, 4.6 Hz), 3.13 (1H, br d, J = 11.9 Hz), 3.11-2.98 (3H, comp), 2.64 (1H, br dd, J = 16.9, 4.1 Hz), 2.59 (1H, ddd, J = 12.4, 4.6, 2.3 Hz), 2.46 (1H, app td, J = 11.5, 4.1 Hz), 1.98 (1H, app t, J = 11.5 Hz), 1.77-1.65 (2H, comp), 1.58 (1H, ddd, J = 13.3, 10.0, 3.2 Hz), 1.49 (1H, app q, J = 11.5 Hz), 1.07 (1H, ddd, J = 13.7, 10.0, 4.1 Hz), 0.94 (3H, d, J = 6.7 Hz), 0.92 (3H, d, J = 6.7 Hz); **^{13}C NMR** (CDCl_3) δ 147.4 (C), 147.1 (C), 129.2 (C), 126.3 (C), 111.4 (CH), 107.8 (CH), 74.6 (CH), 60.9 (CH), 60.0 (CH_2), 55.9 (CH_3), 55.8 (CH_3), 51.9 (CH_2), 41.6 (CH), 40.5 (CH_2), 39.6 (CH_2), 29.1 (CH_2), 25.3 (CH), 24.2 (CH_3), 21.7 (CH_3); **IR** (AT-IR) 3381, 1513, 1261, 1212, 1008, 767 cm^{-1} ; **HRMS** (CI) m/z 320.2219 [$\text{C}_{19}\text{H}_{30}\text{NO}_3$ (M+1) requires 320.2226]. **2-epi-dihydrotetrabenazine** (minor diastereomer): **^1H NMR** (CDCl_3) δ 6.66 (1H, s), 6.58 (1H, s), 4.09 (1H, br d, J = 2.3 Hz), 3.844 (3H, s), 3.841 (3H, s), 3.54 (1H, br d, J = 9.2 Hz), 3.14 (1H, m), 3.00 (1H, m), 2.73-2.56 (3H, comp), 2.46 (1H, m), 2.44 (1H, app dt, J = 13.7, 2.8 Hz), 2.02 (1H, m), 1.76-1.64 (2H, comp), 1.31-1.24 (2H, comp), 1.20-1.13 (1H, m), 0.94 (3H, d, J = 7.0 Hz), 0.92 (3H, d, J = 7.0 Hz); **^{13}C NMR** (CDCl_3) δ 147.4 (C), 147.1 (C), 126.7 (C), 111.4 (CH), 107.9 (CH), 67.9 (CH), 56.4 (CH), 56.2 (CH_2), 55.9 (CH_3), 55.8 (CH_3), 52.4 (CH_2), 39.0 (CH_2), 38.8 (CH_2), 37.6 (CH), 29.0 (CH_2), 24.8 (CH), 22.9 (CH_3 x 2). This data was consistent with previously reported data.^{18,26}

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This publication was made possible by the Arkansas INBRE program, supported by grant funding from the National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (P20 GM103429) (formerly P20RR016460). L.R.O was supported in part by a grant from the Research Corporation for Science Advancement (ID: 21087). Hendrix College's NMR facilities are supported by the National Science Foundation under grant No. 1040470.

References

1. Pletscher A. Science. 1957; 126:507–507. [PubMed: 13467235]
2. Brossi A, Chopard-dit-Jean LH, Schnider O. Helv Chim Acta. 1958; 41:1793–1806.
3. Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P. Nat Rev Drug Discov. 2009; 8:17–18. [PubMed: 19116624]

4. Frank S, Jankovic J. *Drugs*. 2010; 70:561–571. [PubMed: 20329804]
5. Müller T. *Expert Opin Invest Drugs*. 2015; 24:737–742.
6. Zheng G, Dwoskin LP, Crooks PA. *AAPS J*. 2006; 8:E682–E692. [PubMed: 17233532]
7. Ugolev Y, Segal T, Yaffe D, Gros Y, Schuldiner S. *J Biol Chem*. 2013; 288:32160–32171. [PubMed: 24062308]
8. Bernstein AI, Stout KA, Miller GW. *Neurochem Int*. 2014; 73:89–97. [PubMed: 24398404]
9. Kumar A, Lo ST, Öz OK, Sun X. *Bioorg Med Chem Lett*. 2014; 24:5663–5665. [PubMed: 25467156]
10. Lin KJ, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Hsiao IT. *PLoS ONE*. 2013; 8:e75952. [PubMed: 24098749]
11. Zhu L, Liu J, Kung HF. *Bioorg Med Chem Lett*. 2009; 19:5026–5028. [PubMed: 19632829]
12. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, Frey KA, Albin RL. *J Nucl Med*. 2005; 46:936–944. [PubMed: 15937303]
13. Zubieta JK, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, Frey KA. *Biol Psychiatry*. 2001; 49:110–116. [PubMed: 11164757]
14. Kilbourn MR. *Nuc Med Biol*. 1997; 24:615–619.
15. Kilbourn M, Lee L, Borghat TV, Jewett D, Frey K. *Eur J Pharmacol*. 1995; 278:249–252. [PubMed: 7589162]
16. Podurgiel SJ, Nunes EJ, Yohn SE, Barber J, Thompson A, Milligan M, Lee CA, López-Cruz L, Pardo M, Valverde O, Lendent C, Baqi Y, Müller CE, Correa M, Salamone JD. *Neuroscience*. 2013; 250:507–519. [PubMed: 23867769]
17. Boldt KG, Biggers MS, Phifer SS, Brine GA, Rehder KS. *Synth Commun*. 2009; 39:3574–3585.
18. Rishel MJ, Amarasinghe KKD, Dinn SR, Johnson BF. *J Org Chem*. 2009; 74:4001–4004. [PubMed: 19374381]
19. Paek SM, Kim NJ, Shin D, Jung JK, Jung JW, Chang DJ, Moon H, Suh YG. *Chem—Eur J*. 2010; 16:4623–4628. [PubMed: 20235241]
20. Yu QS, Luo W, Deschamps J, Holloway HW, Kopajtic T, Katz JL, Brossi A, Greig NH. *ACS Med Chem Lett*. 2010; 1:105–109. [PubMed: 20694189]
21. Son YW, Kwon TH, Lee JK, Pae AN, Lee JY, Cho YS, Min SJ. *Org Lett*. 2011; 13:6500–6503. [PubMed: 22103629]
22. Johannes M, Altmann KH. *Org Lett*. 2012; 14:3752–3755. [PubMed: 22742980]
23. Reddy NSS, Reddy AS, Yadav JS, Reddy BVS. *Tetrahedron Lett*. 2012; 53:6916–6918.
24. Lee LC, Vander Borghat T, Sherman PS, Frey KA, Kilbourn MR. *J Med Chem*. 1996; 39:191–196. [PubMed: 8568807]
25. Boldt KG, Brine GA, Rehder K. *Org Prep Proc Int*. 2008; 40:379–384.
26. Yao Z, Wei X, Wu X, Katz JL, Kopajtic T, Greig NH, Sun H. *Eur J Med Chem*. 2011; 46:1841–1848. [PubMed: 21396745]
27. Zheng P, Lieberman BP, Choi SR, Plöessl K, Kung HF. *Bioorg Med Chem Lett*. 2011; 21:3435–3438. [PubMed: 21531556]
28. Burns NZ, Baran PS, Hoffmann RW. *Angew Chem, Int Ed*. 2009; 48:2854–2867.
29. Bäckvall, J-E., editor. *Modern Oxidation Methods*. 2. Wiley-VCH; Weinheim: 2011.
30. Boess E, Schmitz C, Klussmann M. *J Am Chem Soc*. 2012; 134:5317–5325. [PubMed: 22338603]
31. Sureshkumar D, Sud A, Klussmann M. *Synlett*. 2009; 2009:1558–1561.
32. Shen Y, Tan Z, Chen D, Feng X, Li M, Guo CC, Zhu C. *Tetrahedron*. 2009; 65:158–163.
33. Shen Y, Li M, Wang S, Zhan T, Tan Z, Guo C-C. *Chem Commun*. 2009:953–955.
34. Zeng T, Song G, Moores A, Li CJ. *Synlett*. 2010; 2010:2002–2008.
35. Ratnikov MO, Xu X, Doyle MP. *J Am Chem Soc*. 2013; 135:9475–9479. [PubMed: 23734676]
36. Huo C, Wu M, Jia X, Xie H, Yuan Y, Tang J. *J Org Chem*. 2014; 79:9860–9864. [PubMed: 25244546]
37. Dhineshkumar J, Lamani M, Alagiri K, Prabhu KR. *Org Lett*. 2013; 15:1092–1095. [PubMed: 23419035]

38. Nobuta T, Fujiya A, Yamaguchi T, Tada N, Miura T, Itoh A. *RSC Adv.* 2013; 3:10189–10192.
39. Tanoue A, Yoo WJ, Kobayashi S. *Org Lett.* 2014; 16:2346–2349. [PubMed: 24725125]
40. Beatty JW, Stephenson CRJ. *Acc Chem Res.* 2015; 48:1474–1484. [PubMed: 25951291]
41. Schultz DM, Yoon TP. *Science.* 2014; 343:1239176. [PubMed: 24578578]
42. Jahn E, Jahn U. *Angew Chem, Int Ed.* 2014; 53:13326–13328.
43. Prier CK, Rankic DA, MacMillan DWC. *Chem Rev.* 2013; 113:5322–5363. [PubMed: 23509883]
44. Shi L, Xia W. *Chem Soc Rev.* 2012; 41:7687–7697. [PubMed: 22869017]
45. Xuan J, Xiao WJ. *Angew Chem, Int Ed.* 2012; 51:6828–6838.
46. Yoon TP, Ischay MA, Du J. *Nat Chem.* 2010; 2:527–532. [PubMed: 20571569]
47. Condie AG, Gonzalez-Gomez JC, Stephenson CRJ. *J Am Chem Soc.* 2010; 132:1464–1465. [PubMed: 20070079]
48. Rueping M, Zhu S, Koenigs RM. *Chem Commun.* 2011; 47:12709–12711.
49. Hari DP, Koenig B. *Org Lett.* 2011; 13:3852–3855. [PubMed: 21744842]
50. Xuan J, Feng ZJ, Duan SW, Xiao WJ. *RSC Adv.* 2012; 2:4065–4068.
51. Rueping M, Koenigs RM, Poschorny K, Fabry DC, Leonori D, Vila C. *Chem—Eur J.* 2012; 18:5170–5174. [PubMed: 22431393]
52. DiRocco DA, Rovis T. *J Am Chem Soc.* 2012; 134:8094–8097. [PubMed: 22548244]
53. Nie SZ, Sun X, Wei WT, Zhang XJ, Yan M, Xiao JL. *Org Lett.* 2013; 15:2394–2397. [PubMed: 23621093]
54. Mathis CL, Gist BM, Frederickson CK, Midkiff KM, Marvin CC. *Tetrahedron Lett.* 2013; 54:2101–2104.
55. Miller LL, Stermitz FR, Becker JY, Ramachandran V. *J Am Chem Soc.* 1975; 97:2922–2923.
56. Baslé O, Borduas N, Dubois P, Chapuzet JM, Chan TH, Lessard J, Li CJ. *Chem—Eur J.* 2010; 16:8162–8166. [PubMed: 20533455]
57. Chow PK, To WP, Low KH, Che CM. *Chem—Asian J.* 2014; 9:534–545. [PubMed: 24203620]
58. Jones KM, Klusmann M. *Synlett.* 2012; 2012:159–162.
59. Freeman DB, Furst L, Condie AG, Stephenson CRJ. *Org Lett.* 2012; 14:94–97. [PubMed: 22148974]
60. Zhao G, Yang C, Guo L, Sun H, Chen C, Xia W. *Chem Commun.* 2012; 48:2337–2339.
61. Rueping M, Vila C, Koenigs RM, Poschorny K, Fabry DC. *Chem Commun.* 2011; 47:2360–2362.
62. Pan Y, Kee CW, Chen L, Tan CH. *Green Chem.* 2011; 13:2682–2685.
63. Kohls P, Jadhav D, Pandey G, Reiser O. *Org Lett.* 2012; 14:672–675. [PubMed: 22260623]
64. Perepichka I, Kundu S, Hearne Z, Li CJ. *Org Biomol Chem.* 2015; 13:447–451. [PubMed: 25372475]
65. Rusch F, Unkel LN, Alpers D, Hoffmann F, Brasholz M. *Chem—Eur J.* 2015; 21:8336–8340. [PubMed: 25917406]
66. Andrews RS, Becker JJ, Gagné MR. *Org Lett.* 2011; 13:2406–2409. [PubMed: 21473567]
67. Bouzide A. *Org Lett.* 2002; 4:1347–1350. [PubMed: 11950359]
68. Baker BA, Bošković ŽV, Lipshutz BH. *Org Lett.* 2007; 10:289–292. [PubMed: 18092793]
69. Pelšs A, Kumpulainen ETT, Koskinen AMP. *J Org Chem.* 2009; 74:7598–7601. [PubMed: 19739611]
70. Ashby EC, Lin JJ. *Tetrahedron Lett.* 1975; 16:4453–4456.
71. Ashby EC, Lin JJ, Kovar R. *J Org Chem.* 1976; 41:1939–1943.
72. Leonard WR, Livinghouse T. *J Org Chem.* 1985; 50:730–732.

Figure 1.
Tetrabenazine and Dihydrotetrabenazine.

A. Cho and Min (*Org. Lett.* **2011**, *13*, 6500-6503) **B. This Work** **Scheme 1.**

Prior Work and Retrosynthetic Analysis of Tetrabenazine.

Scheme 2.
Proof-of-Principle Photoredox Cyclization.

Scheme 3.
Synthesis of (±)-Tetrabenazine.